GEN-003: Phase IIb started

Genocea began a placebo-controlled, U.S. Phase IIb trial to evaluate 2 dose levels of GEN-003 given as 3 injections 21 days apart in about 135 patients. Genocea has rights from Novavax to use the Mat...